🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCompounding & FormulationBeyond-use dating for compounded peptides — my results so far

Beyond-use dating for compounded peptides — my results so far

Dr.BariatricHTX Sun, Nov 24, 2024 at 12:22 AM 12 replies 1,727 viewsPage 1 of 3
This thread is more than 18 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
Nov 24, 2024 at 12:22 AM#1

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

What would genuinely help is knowing what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material.

Not looking for reassurance. Looking for the part I have got wrong.

7 10CarlaRPh_TPA, steph_laguna, fiona_glasgow and 4 others
Reply Quote Save Share Report
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Nov 24, 2024 at 1:25 AM#2

Short answer first, then the reasoning. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

Last edited: Nov 24, 2024 at 4:25 AM
8 11NurseKim_ATL, paul_denver, TinaHashiRN and 5 others
Reply Quote Save Share Report
CanadaChris
Member
234
890
Nov 2024
Toronto, CA
Nov 24, 2024 at 2:28 AM#3
SarahChen_PharmD said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

SarahChen_PharmD has the substance of this right. The condition it depends on is worth stating. Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces a significant clinical difference for that patient. A grid of fixed doses offered to everybody is not that, whatever the intake form says.

9 12maya_sedona, stefan_berlin, Dr.EM_Chicago and 6 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
pam_stl
Member
267
1,123
Oct 2024
St. Louis, MO
Nov 24, 2024 at 3:31 AM#4
Dr.BariatricHTX said:
My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Can confirm the pattern Dr.BariatricHTX describes. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

10 13SleepDoc_PDX, RegAffairsDC, BiostatsBrad and 7 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Nov 24, 2024 at 9:29 AM#5

Adding the clinical framing, because it changes how the question reads.

For compounded supply users considering compounded for the first time: here's a step-by-step guide:

  1. Get a prescription from your doctor (telehealth counts)
  2. Research 503B compounding pharmacies with good community reviews
  3. Verify their FDA registration and inspection history
  4. Request a COA for your specific compound before ordering
  5. Start with a 1-month supply to test
  6. Consider sending a sample to Janoshik for independent verification
  7. Track your response compared to brand (if you were on it previously)
Last edited: Nov 24, 2024 at 3:29 PM
11 14A1cHero_PHX, Dr.RenalNash, LipidDoc_ATL and 8 others
Reply Quote Save Share Report

Similar Threads

503A vs 503B compounding — regulatory framework explained4 replies
Compounded semaglutide stability: accelerated degradation study results6 replies
Lyophilized vs liquid peptides — stability and bioavailability comparison18 replies
Bacteriostatic water sourcing and sterility considerations8 replies
State-by-state compounding pharmacy regulations — 2026 map8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register